Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC

作者：Figlin Robert A^*

来源：Nature Clinical Practice Oncology, 2008, 5(10): 601-609.

DOI：10.1038/ncponc1173

• cancer
• mammalian target of rapamycin (mTOR)
• renal cell carcinoma
• targeted therapy
• temsirolimus

Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) that is approved for the treatment of advanced renal cell carcinoma. mTOR is unique among antitumor drug targets because it is a convergence point for many signaling pathways. Activation of mTOR by various growth signals increases the synthesis of proteins needed for cell-cycle progression and tumor growth. Temsirolimus demonstrates a significant improvement in overall survival in patients with advanced renal cell carcinoma and poor-prognostic features, thereby validating the importance of mTOR in the natural history of this disease. mTOR might also be an important target in other tumor types, and more than 100 ongoing clinical trials are designed to identify additional malignancies that respond to temsirolimus and other mTOR inhibitors, either alone or in combination with other targeted agents or chemotherapy.

• 出版日期2008-10